Future Octopus arms
OCTOPUS Industry Engagement Day!
The world’s first adaptive clinical trial platform in progressive MS evaluating multiple treatments using a multi-arm, multi-stage (MAMS) design.
OCTOPUS are looking for new partnerships as OCTOPUS has the infrastructure and innovative design, to rapidly assess existing and new treatments that could slow down, or ultimately stop, the progression of disability in people with MS.
An OCTOPUS Industry Engagement Day will be held on Thursday 30th January 2025 between 10.00 – 15.00 GMT (with refreshments and lunch provided) at MRC CTU at UCL, 2nd floor, 90 High Holborn, London WC1V 6LJ. If you would like to attend, please fill in a form or email mrcctu.octopus@ucl.ac.uk with your name, position, and company name.
Would your company be interested in working with OCTOPUS?
Adding treatments to an existing trial platform provides significant reduction in set up time as well as increased efficiency.
This is because OCTOPUS has:
- Established governance and management structures.
- A registration of interest portal with >2000 potential participants.
- 88% of participants screened proceeding to randomisation.
- UK sites open and recruiting with full MRI capacity.
OCTOPUS would like to invite you to the OCTOPUS Industry Engagement Day!
This will be held on Thursday 30th January 2025 between 10.00 – 15.00 GMT (with refreshments and lunch provided) at MRC CTU at UCL, 2nd floor, 90 High Holborn, London WC1V 6LJ.
At this meeting you will hear the latest progress and future plans from the OCTOPUS team and if desired opportunity for separate discussions on individual collaborations.
If you would like to attend, please fill in a form or email mrcctu.octopus@ucl.ac.uk with your name, position, and company name.
We hope that you will be able to join us.
Best wishes
Professor Jeremy Chataway, OCTOPUS Chief Investigator (j.chataway@ucl.ac.uk)
Professor Max Parmar, Director of MRC CTU at UCL (m.parmar@ucl.ac.uk)
Professor Frederik Barkhof, UCL (f.barkhof@ucl.ac.uk)
Dr Emma Gray, Director of Research, MS Society (emma.gray@mssociety.org.uk)
On Behalf of the OCTOPUS Trial Management Team
